WarfaRisk β Phase 1 Baselines
This repository contains the three mandatory Phase 1 baselines from WarfaRisk, a nine-phase reproducible ML pipeline for warfarin dose prediction on the public IWPC pharmacogenomic cohorts. These set the performance floor every later-phase model in the project is compared against β no model is reported as an improvement unless it beats the IWPC published equation below (MAE 9.177).
By: Hassan Barmandah, Omar Abdullah Bawazir, Siraj Aldeen Marghalani, Moath Shaat, and Mariam M. AlEissa (corresponding author) β AI Center (AIC), Alfaisal University, Riyadh (with Umm Al-Qura University, Saudi Electronic University)
This is a research artifact, not a validated clinical tool. It has not been evaluated prospectively and has no regulatory status.
Model Description
Three baselines, evaluated on IWPC-6256 (n=6,037 after cleaning, n_test=1,207, fixed 80/20 patient-level split, seed 20260725):
- Naive median-dose predictor β always outputs the training-fold median dose. The performance floor.
- Clinical-only linear regression β ordinary least squares on clinical features only (age, weight, height, indication, comorbidity and comedication flags) β no genetic information.
- IWPC published pharmacogenetic equation β a hand-implemented version of the published square-root-of-dose formula (IWPC, N Engl J Med 2009;360:753-64), the only one of the three that uses genotype (CYP2C9/VKORC1).
Key Contributions
- Performance Floor: every model in this project's Phase 3 ablation is reported against these three baselines, not in isolation
- Genetics-Aware Reference: the IWPC equation baseline is the only one of the three that incorporates genotype, and beats the clinical-only baseline by the margin genetics would predict
- Provenance Discipline: the equation's coefficients are flagged as transcribed from the widely-cited public form (the same form implemented by public calculators such as warfarindosing.org), not verified directly against the original paper's Table 2 β stated plainly rather than silently assumed correct
π How to Use
import joblib # this repo's own artifact format (fit via common/hf_push.py);
# only load .joblib files from this specific, trusted repo
from huggingface_hub import hf_hub_download
model_path = hf_hub_download(
repo_id="HassanB4/warfarin-review-phase1-baselines",
filename="clinical_only_linear_regression.joblib", # see repo files for exact names
)
model = joblib.load(model_path)
prediction = model.predict(your_clinical_features_dataframe)
The IWPC published-equation baseline is a plain Python function (iwpc_published_equation_predict()), not a fitted sklearn estimator β see HasanBGit/WarfaRisk's src/warfarisk/phase1_baselines.py for its implementation.
βοΈ Training Procedure
Training Data
| Split | Samples | Description |
|---|---|---|
| Training | 4,830 | 80% of IWPC-6256, patient-ID-level split |
| Test | 1,207 | Held out, seed 20260725 |
Hyperparameters
| Parameter | Value | Parameter | Value |
|---|---|---|---|
| Cohort | IWPC-6256 | Split Level | Patient ID (not row) |
| Split Seed | 20260725 | Test Fraction | 0.20 |
| Leakage Audit | 11/11 checks passed | Preprocessing Fit | Training fold only |
π Evaluation Results
| Baseline | MAE (mg/week) | RΒ² | PW20 |
|---|---|---|---|
| Naive median dose | 12.339 | -0.048 | 0.342 |
| Clinical-only linear regression | 10.860 | 0.222 | 0.354 |
| IWPC published pharmacogenetic equation | 9.177 | 0.413 | 0.429 |
PW20 = proportion of predictions within 20% of the true dose (IWPC's own clinical-acceptability threshold is β₯0.50 β none of these three baselines clear it; see HassanB4/warfarin-review-phase3-autogluon-iwpc6256 for a model that gets closer).
β οΈ Limitations
- Research-Only: not validated prospectively, no regulatory status
- Equation Provenance: the IWPC-equation baseline's coefficients were transcribed from the widely-cited public form, not independently verified against the original paper's Table 2
- Single Cohort: evaluated on IWPC-6256 only β see
HassanB4/warfarin-review-phase3-autogluon-iwpc1780for the second cohort - Fragmented Ancestry Labels: IWPC-6256's Black/African-American patients are split across three overlapping labels, which affects subgroup-level interpretation of any model trained on this cohort (addressed in this project's Phase 4/5 fairness and calibration analyses)
π Acknowledgements
We thank the PharmGKB / International Warfarin Pharmacogenetics Consortium for the IWPC dataset.
Related Links
π Citation
A paper describing this work is in preparation.
@misc{warfarisk,
title={WarfaRisk: A Reproducible, Ancestry-Stratified Machine Learning Pipeline for Warfarin Dose Prediction},
author={Barmandah, Hassan and Bawazir, Omar Abdullah and Marghalani, Siraj Aldeen and Shaat, Moath and AlEissa, Mariam M.},
year={2026},
note={Manuscript in preparation}
}
π License
This project is licensed under the Apache 2.0 License. This model was fit on IWPC data; the fitted artifact and code are shared under Apache-2.0, but the underlying IWPC dataset is not redistributed by this repository β see HasanBGit/WarfaRisk's data/DATA.md for how to obtain it.
Collection including HassanB4/warfarin-review-phase1-baselines
Evaluation results
- MAE (IWPC published equation) on IWPC-6256 (International Warfarin Pharmacogenetics Consortium)self-reported9.177
- R2 (IWPC published equation) on IWPC-6256 (International Warfarin Pharmacogenetics Consortium)self-reported0.413